Endometrial Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People diagnosed with cervical cancer that is considered suitable for treatment with a combination of radiation and chemotherapy aimed at curing the disease.
- People whose biopsy has confirmed one of three specific cancer types in the cervix: squamous-cell carcinoma, adenocarcinoma, or adeno-squamous cell carcinoma.
- People who have had a pelvic MRI scan performed.
- People who have had both an MRI scan and a PET-CT scan of the abdomen and the area behind the abdominal organs (retroperitoneal space) done at the time of diagnosis.
- People whose cancer is classified as stage IIB to IVA according to international gynaecological cancer staging guidelines (FIGO and TNM).
- People who have had a planning MRI scan done with the radiation applicator in place, as required for the SBRT boost treatment.
- People whose cancer has spread to lymph nodes in the retroperitoneal area, as long as those nodes are below the L1-L2 level of the spine (a specific anatomical landmark — confirm with trial site if unsure).
- People who have signed the study-specific informed consent form.
Who may not be able to join:
- People who have or have had another type of cancer, with the exception of very early-stage cervical cancer (carcinoma in situ) or a common, low-risk form of skin cancer (basal cell carcinoma).
- People whose cervical cancer is a rare type, such as small cell neuroendocrine cancer, melanoma, or other uncommon cervical cancers.
- People whose cancer has spread beyond the retroperitoneal lymph nodes above the L1-L2 spinal level (confirm with trial site).
- People who have previously had radiation treatment to the pelvis or abdomen.
- People who have previously had their uterus removed, either fully or partially (hysterectomy).
- People who are unable to have an MRI scan for medical reasons.
- People with a severe psychiatric condition.
- People with serious, active health conditions in addition to their cancer.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Carlo Greco, MD, Fundaçao Champalimaud
Phone: +351210480200
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Dosimetric Feasibility of SBRT boost; reproducibility of SBRT boost; Inter/intra fractional target motion; Adverse Events; Local control
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.